Is the omicron variant Mother Nature’s way of vaccinating the masses and curbing the pandemic?

Electron microscopic view of the SARS-Cov-2 virus shows the virus clustered and emerging from the surface of cellsThis scanning electron microscope image shows SARS-CoV-2 (round magenta objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19. The virus shown was isolated from a patient in the U.S. Image captured and colorized at NIAID's Rocky Mountain Laboratories (RML) in Hamilton, Montana. Credit: NIAID

By Prakash Nagarkatti, University of South Carolina and Mitzi Nagarkatti, University of South Carolina [This article first appeared in The Conversation, republished with permission]

In the short time since the omicron variant was identified in South Africa in November 2021, researchers have quickly learned that it has three unique characteristics: It spreads efficiently and quickly, it generally causes milder disease than previous variants and it may confer strong protection against other variants such as delta.

This has many people wondering whether omicron could act as a vaccine of sorts, inoculating enough people to effectively bring about herd immunity – the threshold at which enough of the population is immune to the virus to stop its spread – and end the COVID-19 pandemic.

As immunology researchers at the University of South Carolina who are working on inflammatory and infectious diseases, including COVID-19, we find the characteristics of omicron in the pandemic setting particularly intriguing. And it is these characteristics that can help answer that question.

Some 4.73 billion people across the globe – about 61.6% of the world’s population – have received at least one dose of a COVID-19 vaccine. In the United States, 63.4% of the population is fully vaccinated with two doses as of late January 2022, while only 39.9% of Americans have received the booster dose. Such low levels of vaccination resulting from vaccine hesitancy and the complexities of the global vaccine supply chain cast doubt on reaching herd immunity through vaccination anytime soon.

The Conversation

How does omicron mimic a vaccine?

All vaccines work on the principle of training the immune system to fight against an infectious agent. Each vaccine, regardless of how it is made, exposes the human or animal host to the critical molecules used by the infectious agent – in this case, the SARS-CoV-2 virus – to gain entry into the host’s cells.

Some vaccines expose the host only to select portions of the virus. For example, the Pfizer-BioNTech and Moderna vaccines use a molecule called messenger RNA, or mRNA, to encode and produce a fragment of the “spike protein” – the knobby protrusion that is expressed on the outside of SARS-CoV-2 viruses – inside a person’s body. These spike proteins are the key way that the coronavirus invades cells, so the mRNA vaccines are designed to mimic that protein and trigger an immune response against it.

In contrast, some vaccines against other infections, such as chickenpox and measles, mumps and rubella (MMR), expose the host to a “live attenuated” form of the virus. These vaccines use small amounts of a weakened form of the live virus. They mimic a natural infection, trigger a strong immune response and afford lasting resistance to infection.

In some respects, omicron mimics these live attenuated vaccines because it causes milder infection and trains the body to trigger a strong immune response against the delta variant, as shown in a recent study that is not yet peer-reviewed from South Africa.

Deliberate infection with omicron is not the answer

While omicron may share certain characteristics with a vaccine, it should not be considered a viable alternative to the existing vaccines. For one, COVID-19 infection can result in severe illness, hospitalization or death, especially in vulnerable individuals with underlying conditions. It can also cause long-term health effects in some people, called long COVID. In contrast, vaccines currently available against COVID-19 have been tested for safety and efficacy.

The high transmission of omicron combined with ongoing vaccination efforts could help attain herd immunity soon and end the most acute phase of the pandemic. However, there is little chance of it eradicating COVID-19, since all signs point to the likelihood that the virus will become endemic – meaning SARS-CoV-2 will be in circulation but will likely not be as disruptive to society.

Thus far, smallpox is the only infectious disease that has been eradicated globally, which shows how difficult it is to fully eliminate a disease. However, it is easier to control an infection effectively. One example is polio, which has been reduced or eliminated in most countries through vaccination.

What happens when the body meets a virus or vaccine

Both viral infections or the mimicking of a virus through vaccination activate a critical component of the immune system, called B cells, in the body. These cells produce antibodies that bind to the virus, preventing it from infecting cells. These antibodies act much like anti-ballistic missiles that shoot down an incoming virus missile. However, once a virus manages to get inside the body’s cells, antibodies are less effective.

That’s where another key player in the immune system, called killer T cells, come in. These cells can recognize and destroy a cell as soon as it is infected, thereby preventing the virus from multiplying and spreading further. Think of this as an anti-ballistic missile that detects and destroys the factory where missiles are manufactured.

Immunologists believe that antibodies against COVID-19 prevent an individual from catching the infection, while the killer T cells are crucial in preventing severe disease. Despite its numerous mutations, omicron can trigger a strong killer T cell response. This may explain why the COVID-19 vaccines – by triggering the T cells – have provided strong enough immunity against omicron to, in most cases, prevent hospitalization and death.

But, critically, the first wave of antibodies and killer T cells produced during infection or vaccination last for only a few months. This is why recurrent infections of COVID-19 have occurred even in the vaccinated population, and it’s also why booster shots are needed. In contrast, some vaccines – like the one against smallpox – have been shown to trigger immunity that lasts for several years.

Memory immune response

So what exactly triggers strong and lasting immunity? The lifelong immunity seen in certain infections such as smallpox can be explained by a phenomenon called “immunological memory.”

After the B cells and killer T cells first encounter the virus, some of them get converted into what are called memory cells, which are known to live for several decades. As their name suggests, when memory cells “see” a virus again after initial exposure, they recognize it, divide rapidly and mount a robust antibody and killer T cell response, thereby preventing reinfection.

[Over 140,000 readers rely on The Conversation’s newsletters to understand the world. Sign up today.]

For this reason, memory cells are critical for establishing strong, long-lasting immunity. This is evidenced from studies with smallpox in which people that were infected or vaccinated were found to have the antibody response even after 88 years! Why some infections or vaccines trigger long-lasting memory and others do not is under active investigation. Because COVID-19 is only two years old, we researchers don’t know yet how long the memory B and T cells last. Based on recurrent infections, it looks like longer-term immunity does not last very long, but that could also in part be due to the evolution of new variants.

All of these considerations leave room for hope that when new variants of SARS-CoV-2 inevitably arise, omicron will have left the population better equipped to fight them. So the COVID-19 vaccines combined with the omicron variant could feasibly move the world to a new stage in the pandemic – one where the virus doesn’t dominate our lives and where hospitalization and death are far less common.

Prakash Nagarkatti, Professor of Pathology, Microbiology and Immunology, University of South Carolina and Mitzi Nagarkatti, Professor of Pathology, Microbiology and Immunology, University of South Carolina

This article is republished from The Conversation under a Creative Commons license. Read the original article.